In conclusion, the use of the P16, RASSF1A, APC, RARβ, DAPK, CDH13, and MGMT methylation are exceedingly promising and could become useful biomarkers for blood-based screening and detection of NSCLC in the clinical practice. This evidence concerns the gene RASSF1 and non-small cell lung carcinoma.